Revelation Biosciences Reports Improved Financial Results

Revelation Biosciences, Inc. (NASDAQ:REVB) reported its financial outcomes for the periods ending September 30, 2025. The clinical-stage company, focusing on inflammation management, announced a notable financial increase due to financing efforts and a significant study result.

The company gained $9.6 million from warrant inducement in September, bolstering their cash position to $12.7 million, up from $6.5 million at the end of 2024. Revelation's net loss reduced to $1.9 million for the three months ending September 30, 2025, compared to $2.2 million a year earlier.

The PRIME clinical study's results and secured funding validates the potential of Gemini, a proprietary formulation aimed at treating various inflammatory conditions. The company plans to discuss Gemini's registration path with the FDA, enhancing potential shareholder value.